[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CARsgen Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":143},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,35,55,85,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":4},"100579557","long-term-follow-up-observational-study-in-patients-treated-with-gene-modified-t-cell-therapy-100579557",false,"NCT06825845","Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy","Inclusion Criteria:\n\n\\- 1. All patients who have received at least one GM T-cell infusion in the parent clinical study or in the post-approval setting.\n\n2\\. Patients must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For patients incapable of providing consent, the signed ICF of their legally accepted guardians must be obtained.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study.","ALL",{"count":17,"type":18},1500,"ESTIMATED","OBSERVATIONAL","This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available product. In this study, patients will be followed for up to 15 years after last GM T-cell infusion for the evaluation of delayed adverse events (AEs), vector persistence, potential risk for integration, and survival time due to GM T-cell exposure.",[22],"Relapsed or Refractory Multiple Myeloma","NOT_YET_RECRUITING","2025-02-08",{"date":26,"type":27},"2025-02-13","ACTUAL",{"date":29,"type":18},"2025-03-31",{"date":31,"type":18},"2040-06-30",{"name":33,"class":34},"CARsgen Therapeutics Co., Ltd.","INDUSTRY",{"id":36,"slug":37,"hasResults":11,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":4,"eligibilityCriteria":40,"healthyVolunteers":11,"sex":15,"minAge":41,"maxAge":4,"enrollmentInfo":42,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":44,"conditions":45,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100566791","a-real-world-observational-study-zevorcabtagene-autoleucel-injection-in-patients-with-relapsedrefractory-multiple-myeloma-100566791","NCT06659770","A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Subjects with refractory\u002Frelapsed multiple myeloma who meet product indication criteria and have received commercialized zevor-cel infusion.\n3. Voluntary participation in this study and willingness to sign the informed consent form, for subjects incapable to provide consent, informed consent must be obtained from their legally acceptable guardians.\n\nExclusion Criteria:\n\n1\\. There were no specific exclusion criteria for this study。","18 Years",{"count":43,"type":18},200,"This study is a single-arm, open-label, multicenter, post-marketing, Phase IV, prospective, observational clinical trial to evaluate the efficacy and safety of the post-marketing product zevor-cel as treatment for subjects with R\u002FR MM in the real world.",[46],"Relapsed\u002FRefractory Multiple Myeloma","2024-10-24",{"date":49,"type":27},"2024-10-26",{"date":51,"type":18},"2024-10",{"date":53,"type":18},"2027-12-31",{"name":33,"class":34},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":15,"minAge":41,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100559184","phase-1-ct011-autologous-car-t-cells-in-patients-with-hepatocellular-carcinoma-at-risk-of-recurrence-after-surgical-resection-100559184","NCT06560827","CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection","A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection","Inclusion Criteria:\n\nTo be included in the trial, participants must meet all of the following criteria:\n\n1. Volunteer to participate in the clinical trial; fully understand and are informed of this trial and sign the informed consent form; Willing to follow and able to complete all trial procedures;\n2. Age 18-75 years, inclusive, male or female;\n3. Initially diagnosed with CNLC stage IIIa HCC with any of the following vascular tumor thrombi and absence of atrial tumor thrombi on preoperative imaging:\n\n   * Portal vein tumor thrombus (PVTT);\n   * Hepatic vein tumor thrombus (HVTT);\n   * Inferior vena cava tumor thrombus (IVCTT);\n4. Has undergone surgical resection:\n\n   * Pathological evaluation of surgical resection specimen with negative margins;\n   * Preoperative conversion\u002Fneoadjuvant therapy and\u002For postoperative therapy are allowed;\n5. The participant has recovered from liver resection and postoperative progressive increase in AFP level(including: a. AFP increase of at least 20% in any 3 months after surgery; or b. AFP increase of ≥ 10% in any 2 consecutive tests after surgery) with a potential tendency to recurrence as assessed by the investigator.\n6. Tumor tissue samples positive for GPC3 by immunohistochemistry (IHC) (staining intensity ≥ 1 +, percentage of stained tumor cells ≥ 10%);\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 7 days prior to apheresis);\n8. Child-Pugh score ≤ 7 points (within 7 days prior to apheresis);\n9. Estimated survival \\> 12 weeks;\n10. Adequate venous access for apheresis;\n11. Laboratory test results within 7 days prior to apheresis should meet the following criteria (if the laboratory test results do not meet the following criteria, a repeat test within 1 week is allowed; if the laboratory test results still do not meet the criteria, it will be considered a screening failure):\n\n    * Hematology (without transfusion, platelet transfusion, colony-stimulating factor and other supportive treatment within 7 days before detection, except recombinant human erythropoietin): neutrophil count (ANC) ≥ 1.5 × 109\u002FL, lymphocyte count (LY) ≥ 0.5 × 109\u002FL, platelet count (PLT) ≥ 75 × 109\u002FL, hemoglobin (Hb) ≥ 9.0 g\u002FdL; The results of hematology within 24 hours before apheresis shall also meet this standard;\n    * Blood chemistry: serum creatinine ≤ 1. 5 × upper limit of normal (ULN), endogenous creatinine clearance ≥ 40 mL\u002Fmin (using Cockcroft-Gault formula), alanine aminotransferase (ALT) ≤ 5×ULN, aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (ALP) ≤ 5 × ULN, total bilirubin (TBil) ≤ 3 × ULN, serum albumin (ALB) ≥ 28 g\u002FL, and serum lipase and amylase ≤ 2 × ULN;\n    * Prothrombin time (PT) prolongation ≤ 4 s;\n12. Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to remain abstinent or use highly effective and reliable contraception (\\\u003C 1% failure rate per year) during the treatment period and for at least 1 year after the last dose of trial treatment, during which time they must not donate eggs:\n\n    * Women of childbearing potential are defined as women who have not reached post-menarche but have not reached a post-menopausal state (no menses for ≥ 12 consecutive months, with no cause other than menopause) and who have not been permanently infertile due to surgery (removal of ovaries, fallopian tubes, and\u002For uterus) or other reasons (e.g. M ü llerian agenesis, etc.) as determined by the investigator;\n    * Contraceptive methods with an annual failure rate of \\\u003C 1% include: bilateral tubal ligation, male sterilization, approved hormonal contraceptives, hormone-releasing intrauterine devices, copper-containing intrauterine devices; Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation rhythm methods) and withdrawal are not adequate methods of contraception.\n13. Male participants who are sexually active with a female of childbearing potential, who have not had a vasectomy, must agree to remain abstinent or to use contraception (e.g., condoms in combination with other contraceptive measures to achieve an annual failure rate of \\\u003C 1%, see inclusion criterion # 12) during the treatment period and for 1 year after the last dose of study treatment and refrain from donating sperm during this period.\n\nExclusion Criteria:\n\nParticipants were not included in the trial if they met any of the following criteria:\n\n1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed hepatocellular-cholangiocarcinoma;\n2. Intrahepatic recurrence or extrahepatic metastasis, or residual hepatocellular carcinoma detected before apheresis (imaging evidence according to RECIST v1.1);\n3. More than 2 years since surgical resection;\n4. Pregnant or lactating females;\n5. Positive test results for any of the following: human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, hepatitis C virus (HCV) ribonucleic acid (RNA), hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) positive and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] ≥ 1000 IU\u002FmL (HBsAg-positive or HBcAb-positive participants must receive antiviral therapy), cytomegalovirus (CMV) DNA, Epstein-Barr virus (EBV) DNA;\n6. Any uncontrolled active infection, including but not limited to active tuberculosis, infectious diseases requiring systemic treatment, etc.; Patients who use drugs to prevent infection can be enrolled at the discretion of the investigator;\n7. Subjects with clinically significant abnormal thyroid function (free triiodothyronine \\[FT3\\], free thyroxine \\[FT4\\] and serum thyroid stimulating hormone \\[TSH\\] for serum thyroid hormones, and total thyroxine \\[TT4\\] and total triiodothyronine \\[TT3\\] for serum thyroid hormones if necessary) judged by the investigator and not suitable for entry into the trial after assessment; Patients with stable thyroid function after treatment can be considered for inclusion;\n8. Previous or current hepatic encephalopathy;\n9. Presence of clinically significant massive abdominal\u002Fpleural effusion, defined as: positive signs of pleural\u002Fperitoneal effusion on physical examination or pleural\u002Fperitoneal effusion requiring intervention (e.g., paracentesis or drug therapy) for control;\n10. Toxicities caused by previous treatment have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ Grade 1, except for alopecia, pigmentation, other laboratory abnormalities that do not affect the tolerability of the participants as judged by the investigator;\n11. Received anti-tumor treatment for the disease under study within 2 weeks prior to apheresis, including but not limited to surgery, systemic drug therapy (or within 5 half-lives of the drug, whichever is shorter), radiotherapy, interventional therapy, etc.;\n12. Received immunotherapy including anti-PD-1\u002FPD-L1, anti-CTLA-4, or any other investigational therapy within 4 weeks (or within 5 half-lives of the drug, whichever is shorter) prior to apheresis;\n13. Previously received any cell therapy (including CAR-T cells, TCR-T cells, TILs, etc.);\n14. Received systemic glucocorticoid therapy within 7 days prior to apheresis; Patients with recent or current use of inhaled or topical corticosteroids and physiologic dose replacement therapy may be enrolled;\n15. Vaccination with live or live attenuated vaccines within 4 weeks prior to apheresis or planned during the trial;\n16. Known active autoimmune disease, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, interstitial lung disease, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, multiple sclerosis, glomerulonephritis, etc.; Or other participants who require chronic use of immunosuppressive therapy;\n17. Participants with a history of organ transplantation, allogeneic hematopoietic stem cell transplantation or awaiting organ transplantation;\n18. Previous allergies to immunotherapy, tocilizumab, cyclophosphamide or fludarabine and other related drugs, previous history of severe allergies, or known allergies to components of CT011 cell infusion preparation (such as albumin or dimethyl sulfoxide, etc.);\n19. Presence of central nervous system metastasis or related symptoms, or clinically significant central nervous system disease or abnormal neurological examination results or psychiatric disease;\n20. Need for long-term anticoagulation\u002Fthrombolysis\u002Fantiplatelet therapy (such as warfarin, heparin, rivaroxaban, aspirin, dipyridamole, clopidogrel, etc.); Patients receiving prophylactic anticoagulation to maintain patency of venous access devices may be included in this trial;\n21. Major surgical procedure or significant trauma within 4 weeks prior to apheresis, or anticipation of the need for major surgery during the trial;\n22. Pre-apheresis oxygen saturation ≤ 95% (under room air, the finger pulse oxygen test is accepted);\n23. Any other disease, metabolic disorder, sign, or test result that contraindicates the use of the trial drug, affects the interpretation of the results, or places the participant at high risk of treatment complications, which, as assessed by the investigator, would not be appropriate for participation in the trial, including but not limited to: poorly controlled diabetes mellitus (treated glycosylated hemoglobin \\[HbA1c\\] \\> 8%), poorly controlled hypertension (blood pressure \\> 160 mmHg\u002F100 mmHg), hypotension requiring vasopressor medication, uncontrolled congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV), Left ventricular ejection fraction \\[LVEF\\] \\\u003C 50%, myocardial infarction within the past 6 months, arrhythmia not well controlled by drug therapy, unstable angina pectoris, or other serious heart disease, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease or clinically significant pulmonary function test abnormality as judged by the investigator; Presence of currently gastrointestinal obstruction or active\u002Funstable gastrointestinal ulcer, gastrointestinal bleeding within the past 3 months or with bleeding risk (e.g., esophageal and gastric varices caused by portal hypertension or bleeding tendency; patients with liver cirrhosis are recommended to undergo additional gastroscopy during the screening period according to the judgment of the investigator to determine the condition of varices); The participant is in a severe inflammatory state overall (e.g., increased neutrophil count and\u002For C-reactive protein, fever ≥ 38 ℃ unrelated to the underlying disease);\n24. Presence of other incurable malignancies within the past 5 years or at the same time, except for appropriately treated cervical carcinoma in situ, skin basal cell carcinoma and other malignancies with very low risk of metastasis\u002Fdeath;\n25. Inability or unwillingness of the participant to comply with the requirements of the trial protocol as assessed by the investigator.","75 Years",{"count":64,"type":18},30,"INTERVENTIONAL",[67],"PHASE1","A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.",[70],"HCC",[72,73,70,74],"IIIa","GPC3","CT011","RECRUITING","2024-08-15",{"date":78,"type":27},"2024-08-19",{"date":80,"type":27},"2023-10-08",{"date":82,"type":18},"2027-06-30",{"name":33,"class":34},15,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":41,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":65,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100509268","phase-1-a-study-to-evaluate-the-efficacy-and-safety-of-ct041-after-adjuvant-chemotherapy-for-pancreatic-cancer-100509268","NCT05911217","A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer","Inclusion Criteria:\n\n1. Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures;\n2. Aged 18 to 79 years;\n3. Histologically confirmed pancreatic ductal adenocarcinoma;\n4. Macroscopic complete tumor removal (R0 or R1 resection);\n5. Postoperative pathological stage (pTNM): T1-3, N0-2, M0;\n6. Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;\n7. Subjects had recovered from surgery and had received 3 months of standard adjuvant therapy;\n8. Abnormal CA19-9 level;\n9. With sufficient venous access for leukapheresis collection;\n10. ECOG performance status score 0-1;\n11. Adequate organ function;\n12. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;\n\nExclusion Criteria:\n\n1. Prior neoadjuvant therapy for pancreatic cancer;\n2. Subjects with borderline resectable pancreatic cancer;\n3. Present or past history of metastatic or locally recurrent pancreatic cancer;\n4. Evidence of malignant ascites;\n5. Subjects had diseases that may interfere with CA19-9 level, including but not limited to cholangitis, pancreatitis, obstructive jaundice, etc.\n6. Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study;\n7. Pregnant or lactating women;\n8. Positive serology for HIV, Treponema pallidum or HCV;\n9. Any active infections, including but not limited to active tuberculosis, HBV, EBV, CMV, COVID-19 infections;\n10. Clinically significant thyroid dysfunction;\n11. Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history;\n12. Subjects who may be at high risk for potential digestive tract bleeding or perforation;\n13. Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy;\n14. Subjects who have a history of organ transplantation or are awaiting organ transplantation;\n15. Subjects who require anticoagulant therapy;\n16. Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study;\n17. Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period;\n18. Previously received any gene-modified cell therapies (including CAR T, TCR T);\n19. Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators;\n20. Subjects with oxygen saturation ≤ 95%;\n21. Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities;\n22. Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;\n23. Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study;\n24. Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.","79 Years",{"count":94,"type":18},20,[67],"An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.",[98],"Pancreatic Cancer",[100,98,101,102,103],"Adjuvant therapy","Claudin18.2","CLDN18.2","CAR T cell","2024-05-24",{"date":106,"type":27},"2024-05-28",{"date":108,"type":27},"2023-07-11",{"date":110,"type":18},"2026-12-31",{"name":33,"class":34},8,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":41,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":65,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":4},"100541718","phase-1-anti-gprc5d-car-t-cells-ct071-in-participants-with-rrmm-or-rrppcl-100541718","NCT06333509","Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL","A Phase 1\u002F2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed\u002FRefractory Multiple Myeloma (RRMM) or Relapsed\u002FRefractory Primary Plasma Cell Leukemia (RRpPCL)","Inclusion Criteria:\n\n* Voluntarily signed consent;\n* Age of ≥ 18;\n* Willing and able to adhere to trial visit schedule and other protocol requirements\n* Received sufficient prior lines of therapy;\n* RRMM participants must have received treatment with at least one proteasome inhibitor, one IMiD and CD38 anti body, must be refractory to the last line of therapy, must have achieved a response (PR or better) to a least 1 prior treatment line;\n* RRpPCL participants must have received at least one prior line of therapy.\n* Participants must have documented diagnosis of RRMM or RRpPCL.\n* The participants should have measurable disease.\n* Estimated life expectancy \\> 12 weeks;\n* ECOG performance score 0-1;\n* Participants should have bone marrow reserve, renal and hepatic functions;\n* Sufficient venous access for apheresis collection, and no other contraindications to apheresis;\n* Must be able to stop any anticancer therapy for planned apheresis collection\n* Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception for at least 12 months after T cell infusion;\n* Men must be willing to use effective and reliable method of contraception for at least 12 months after T cell infusion.\n\nExclusion Criteria:\n\n* Any significant condition(s), laboratory abnormality or psychiatric illness that would impair the ability of the participant to receive or tolerate the planned treatment or in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Pregnant or lactating women;\n* HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection;\n* Any uncontrolled active infection;\n* AEs from previous treatment that have not recovered;\n* Participants who have had anti-GPRC5D targeted agents;\n* Participants who have received autologous stem cell transplantation 12 weeks before apheresis;\n* Participants who have received allogenic stem cell transplantation within 6 months of apheresis;\n* Participants who have graft versus host disease (GvHD);\n* Participants who have received steroids within 14 days of apheresis or lymphodepletion;\n* Participants who have plasma cell leukemia secondary to multiple myeloma, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or clinically significant symptomatic immunoglobulin light chain (AL) amyloidosis with evidence of end-organ damage;\n* Participants who have been administered live attenuated vaccine 4 weeks before apheresis or lymphodepletion;\n* Participants who are allergic to fludarabine, cyclophosphamide, tocilizumab, dimethyl sulfoxide (DMSO) or CT071;\n* Participants who have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients;\n* Participants who require supplemental oxygen;\n* Participants who have clinically significant pulmonary conditions;\n* Participants who are known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy;\n* Participants with malignancies in addition to MM\u002FpPCL;\n* Participants who have central nervous system (CNS) metastases or CNS involvement;\n* Participants with a history of stroke or seizures within 6 months prior to apheresis;\n* Participants who have undergone major surgery 14 days prior to apheresis or within 28 days of CT071 administration.",{"count":121,"type":18},166,[67,123],"PHASE2","A Phase 1\u002F2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed\u002Frefractory multiple myeloma or relapsed\u002Frefractory primary plasma cell leukemia.",[126,127],"Multiple Myeloma","Primary Plasma Cell Leukemia",[129,126,130,131,132,133,134,135],"CAR-T","Primary plasma cell myeloma","CT071","GPRC5D","anti-GPRC5D","genetically modified T-cells","hematologic cancer","2024-03-25",{"date":138,"type":27},"2024-03-27",{"date":140,"type":18},"2024-04-15",{"date":53,"type":18},{"name":33,"class":34},""]